Clinical trial · Observational
Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy
Identification and Evaluation of the Potential Biomarkers on Circulating Tumor Cells and Tumor Related Rare Cells in Cancer Patients Undergoing Immunotherapy
NCT03434912CI-TRIAL-00034397unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome. The secondary objective is to explore whether the changes of tumor related rare cells associates clinical outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CTC and Tumor Related Rare Cell | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Circulating tumor cell
- timeFrame
- 1 years
- description
- Isolation and analysis of circulating tumor cells before and after immunotherapy
Secondary outcomes (1)
- measure
- tumor related rare cell
- timeFrame
- 1 years
- description
- Isolation and analysis of tumor related rare cells before and after immunotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: 1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study. 2. Over 20 years of age. 3. Cancer patients on immune checkpoint inhibitors. Exclusion Criteria: 1. Subjects who have other cancer history 2. Pregnant females 3. Subjects with active, known or suspected autoimmune disease. 4. Known history of human immunodeficiency virus (HIV)
References
Publications (0)
Data not yet available
No reference posted for this study.